PHILIP TRAVIS SAGER
Medical Practice in San Francisco, CA

Pharmaceutical Consultant and Chair, Scientific Committee, Cardiac Safety Research Consortium at Sager Consulting Partners

Pharmaceuticals

Gilead Sciences 2009 - 2010 - VP and Head, CardioPulmonary and Metabolic Clinical Development CardioDx 2008 - 2009 - Chief Medical Officer AstraZeneca Jan 2004 - Feb 2008 - Executive Director, Clinical Development AstraZeneca R&D 2004 - 2008 - Executive Director Schering-Plough Sep 2001 - Jan 2004 - Director, CV Research UCLA School of Medicine 1990 - 2001 - Tenured Faculty Member

Yale University School of Medicine 1982 - 1988
Yale University School of Medicine 1978 - 1982
MD, Internal Medicine, Cardiology, EP Massachusetts Institute of Technology 1973 - 1977
BS, BS, Chemistry, Biology The Dalton School 1970 - 1973
High School

Clinical Drug Development, Biotechnology, CV Safety and QT Issues, Drug safety, Cardiac safety, Medical Affairs, Personalized Medicine, CV Regulatory Issues, Lipids, Diabetes, Arrhythmias, Congestive Heart Failure, Ischemia, Ischemic Heart Disease, anti-platelet and anticoagulant medications, ICH E14 PhRMA Expert Working Group Topic Leader, Chair of the Scientific Oversight Committee of the FDA-sponsored Cardiac Safety Research Consortium, Phi Beta Kappa, AOA, MD, FACC, FAHA, FHRS, FACP

Invited to chair and lecture at US and International Symposia.Meetings, Phi Beta Kappa, Alpha Omega Alpha, Who's Who in the World, America, US Healthcare

Cardiology, Clinical Cardiac Electrophysiology

719 Carolina St, San Francisco 94107
(650) 450-7477 (Phone), (415) 970-9593 (Fax)

Cardiovascular Disease, 1987, Clinical Cardiac Electrophysiology, 1992, Internal Medicine, 1985

Healthgrades Honor Roll

English